BUILDING STAKEHOLDER ENGAGEMENT THROUGH EAPs Download our guide on leveraging Early Access Programs to engage healthcare professionals, payers, and empower eligible patients with early access to innovative therapies. Gain valuable insights, contribute to real-world evidence, [...]
International Recognition Procedure From January 2024, the MHRA is adopting the International Recognition Procedure, reflecting a strategic pivot towards an independent and collaborative regulatory framework for swift and secure drug authorizations in the UK. Our [...]
Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (VPAG) The new VPAG scheme is due to come in effect in January 2024 lasting for 5 years. The scheme, which has been agreed between the [...]
Navigating the Future of EU Joint Health Technology Assessments With the Health Technology Assessment (HTA) landscape undergoing transformation in January 2025, it's essential to prepare your pipeline for what lies ahead. Our Market Access team [...]